YMAB
Y-mAbs Therapeutics
YMAB
YMAB
Delisted
YMAB was delisted on the 15th of September, 2025.
95 hedge funds and large institutions have $132M invested in Y-mAbs Therapeutics in 2023 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 30 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
1.17% more ownership
Funds ownership: 43.48% → 44.65% (+1.2%)
7% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
95
Holding in Top 10
1
Calls
$36K
Puts
$11K
Top Buyers
| 1 | +$3.29M | |
| 2 | +$1.84M | |
| 3 | +$1.73M | |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.63M |
| 5 |
Goldman Sachs
New York
|
+$1.44M |
Top Sellers
| 1 | -$2.15M | |
| 2 | -$1.99M | |
| 3 | -$1.9M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.86M |
| 5 |
JPMorgan Chase & Co
New York
|
-$1.07M |